A next-generation human lymphatic filariasis vaccine candidate, rBmHAXT, for clinical development
npj Vaccines·
- DOI
- 10.1038/s41541-026-01497-7
- PMID
- 42414326
- PMCID
- —
- OpenAlex
- W4411503046
- Study type
- Journal article
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Publication version
This article has a linked preprint
The relationship comes from Crossref version metadata. Compare both records because findings and wording may have changed between versions.
Open linked preprint →Why this research matters now
Successful stabilization and scalable preparation of this candidate could streamline the transition from laboratory research to regulated clinical testing for filarial disease prevention.
Structured evidence summary
Research question
The investigation addresses how to optimize the production and formulation of the rBmHAXT protein to prevent aggregation during large-scale manufacturing while preserving its protective properties.
Study design
This preclinical project utilized a murine model to assess the immunogenicity, protective efficacy, and accelerated thermal stability of three engineered protein variants.
Population and setting
Animal subjects were restricted to a controlled laboratory mouse model for all experimental evaluations.
Main findings
Introducing cysteine-to-serine substitutions effectively eliminated antigen aggregation during scale-up. The resulting construct preserved the original biological activity and immune response profiles observed in mice. Furthermore, this modified version exhibited sustained structural integrity at ambient temperatures over a six-week observation window.
Public-health relevance
Successful stabilization and scalable preparation of this candidate could streamline the transition from laboratory research to regulated clinical testing for filarial disease prevention.
Important limitations
Conclusions derive solely from short-term in vitro stability metrics and murine challenge studies, leaving human pharmacokinetics and long-term safety unassessed.
GIDS interpretation
The manuscript documents early-stage developmental work focused on bioprocess engineering and preliminary biological validation. It offers technical context for future investigational candidates without reflecting active epidemiological tracking or implementation outcomes.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 9 auditable classifier relationships to diseases, places, topics, and study design.